Related Experiment Videos
Analgesia and COX-2 inhibition
R A Dionne1, A A Khan, S M Gordon
1National Institute of Dental and Craniofacial Research, NIH, Washington, USA. dionnera@yahoo.com
Clinical and Experimental Rheumatology
|November 7, 2001
Summary
Non-steroidal anti-inflammatory drugs (NSAIDs) provide pain relief, but toxicity is a concern. This study shows that inhibiting cyclooxygenase-2 (COX-2) selectively reduces prostaglandin E2 (PGE2) and alleviates pain, suggesting COX-2
Area of Science:
- Pharmacology
- Pain Management
- Inflammation Research
Background:
- Non-steroidal anti-inflammatory drugs (NSAIDs) are widely used for pain and inflammation.
- Chronic NSAID use is limited by toxicity, necessitating investigation into selective agents.
- Cytokine release at injury sites influences NSAID efficacy and side effects.
Purpose of the Study:
- To assess the relationship between cytokines and NSAID analgesia.
- To compare the in vivo selectivity of a COX-2 inhibitor (celecoxib) versus a dual inhibitor (ketorolac).
- To investigate the role of prostaglandin E2 (PGE2) in NSAID-mediated pain relief.
Main Methods:
- Utilized an oral surgery pain model in rats.
- Employed submucosal microdialysis to measure prostaglandin E2 (PGE2) and thromboxane B2 (TxB2).
- Administered ketorolac (dual COX-1/COX-2 inhibitor) and celecoxib (selective COX-2 inhibitor) and assessed pain and biomarker levels.
Main Results:
- PGE2 production followed a biphasic pattern, with early COX-1 activity and later COX-2 expression.
- Ketorolac (30 mg) reduced pain and PGE2; lower dose (1 mg) reduced pain but not PGE2.
- Celecoxib selectively reduced PGE2 (associated with COX-2) without affecting TxB2 (COX-1 biomarker), while providing analgesia.
Conclusions:
- Demonstrated in vivo assessment of selective COX-2 inhibitor effects.
- Suppression of COX-2 mediated PGE2 is temporally linked to NSAID analgesia.
- Selective COX-2 inhibition offers a potential therapeutic advantage in pain management.